GlassScriptPhysician profile
Pilar Berg
NPI 1700966918
$4,516.26
in general payments reported to CMS, 2019-2025
29 companies · $210 in 2025
The $210 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,328 · 2022: $980 · 2023: $1,161 · 2024: $837 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189 · Education: $18.96.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,188.72 |
| Education | $18.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,362.90 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $695.22 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $360.40 | 2021-2024 | Entyvio |
| Qol Medical, LLC | $219.43 | 2021-2025 | Sucraid, Sucraid |
| Celgene Corporation | $216.05 | 2021-2024 | Zeposia |
| Pfizer INC. | $194.98 | 2021-2024 | |
| Janssen Biotech, INC. | $190.59 | 2021-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $172.17 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $143.16 | 2021-2022 | |
| Ardelyx, INC. | $130.97 | 2022-2023 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $122.81 | 2021-2023 | Ocaliva |
| Genzyme Corporation | $87.68 | 2022-2024 | |
| Ferring Pharmaceuticals INC. | $83.59 | 2022-2023 | Cimzia, Rebyota |
| Aimmune Therapeutics, INC. | $67.93 | 2024-2025 | Zenpep |
| Braintree Laboratories, INC. | $63.07 | 2021-2024 | Sutab, Suflave |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $59.53 | 2023-2025 | Voquezna |
| Fresenius Kabi USA, LLC | $57.68 | 2023 | Idacio |
| Lilly USA, LLC | $53.05 | 2023-2024 | Omvoh |
| Amgen INC. | $41.90 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $33.62 | 2022-2024 | Dificid |
| Intra-Sana Laboratories | $25.52 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $20.75 | 2024 | Iqirvo |
| Celltrion USA INC. | $18.96 | 2024 | Zymfentra |
| Ironwood Pharmaceuticals, INC | $18.84 | 2023 | Linzess |
| Vivus LLC | $16.65 | 2021 | |
| Myriad Women'S Health, INC. | $16.62 | 2023 | Myrisk |
| Mallinckrodt Hospital Products INC. | $15.81 | 2025 | Terlivaz |
| Sandoz INC. | $14.90 | 2023 | Hyrimoz |
| Redhill Biopharma INC. | $11.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pilar Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.